Roivant Launches New Vant to Develop Eisai’s RVT-2001 for Myelodysplastic Syndromes
Shots:
- Roivant’s launched new subsidiary, Hemavant, that entered into a licensing agreement with Eisai for exclusive global rights to RVT-2001 for the treatment of transfusion-dependent anaemia in patients with lower-risk myelodysplastic syndromes
- Hemavant plans to develop RVT-2001 as an oral therapy with expected P-I/II study initiation in H1’22 with initial data expected in 2023
- RVT-2001 showed RBC-TI rate of >30% in a P-I/II trial involving a subset of 19 patients with lower-risk, transfusion-dependent MDS, 15 out of 19 had prior treatment with BMS’ Revlimid (lenalidomide) and/or hypomethylating agents
Ref: Roivant | Image: Fierce Biotech
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
